{"entity":{"id":"nct05866432","kind":"trial","name":"Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases","aka":["TUXEDO-2"],"tldr":"A phase 2 trial of datopotamab deruxtecan in triple-negative breast cancer, run by Medical University of Vienna, now recruiting.","summary":"Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases is a phase 2, interventional study registered as NCT05866432 by Medical University of Vienna, with a registry enrolment figure of 20 participants, started 2023-07-01 and due to reach its primary completion in 2026-05-23. Interventions recorded: Datopotamab deruxtecan. Conditions listed: Breast Cancer Stage IV. Triple-negative eligibility wording from the registry: \"* Triple-negative disease as defined by immunohistochemistry (IHC) and/or c-erb-B2 gene amplification status\". Sites: Austria. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05866432","url":"https://clinicaltrials.gov/study/NCT05866432"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early","brain-metastases"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["datopotamab-deruxtecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05866432","phase":"2","setting":"Phase II Study of Datopotamab-Deruxtecan (Dato-DXd; DS-1026a) in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases","sponsor":"Medical University of Vienna","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05866432/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"term":[{"id":"brain-metastases","kind":"term","name":"Brain metastases (intracranial disease)","route":"/terms/brain-metastases/"},{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"}]}}